Artigo Revisado por pares

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

2017; Elsevier BV; Volume: 152; Issue: 5 Linguagem: Inglês

10.1016/s0016-5085(17)31535-4

ISSN

1528-0012

Autores

Zsuzsanna Kürti, Barbara D. Lovász, Mariann Rutka, Zsuzsanna Végh, K Gecse, Klaudia Farkas, J Banai, László Bene, Petra A. Golovics, Lóránt Gönczi, Beáta Gasztonyi, Tünde Kristóf, L. Lakatos, Pál Miheller, Károly Palatka, Árpád V. Patai, Mária Papp, Á Salamon, T Szamosi, Zoltán Szepes, Gábor Tamás Tóth, Áron Vincze, Balázs Szalay, Tamás Molnár, Péter L. Lakatos,

Tópico(s)

Statistical Methods in Clinical Trials

Referência(s)
Altmetric
PlumX